Compare Apple Inc (AAPL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Zoetis Inc — how do they compare? Apple Inc trades at $301.44 (market cap $4.45T), while Zoetis Inc trades at $72.4 (market cap $31.14B). The key difference: Apple Inc is far larger — about 142.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| AAPL | ZTS | |
|---|---|---|
Market Cap | $4.45T | $31.14B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $156.76 |
52-Week Low | $224.90 | $71.91 |
Enterprise Value | $4.47T | $38.70B |
Dividend Yield | 0.35% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.
The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
